Peter C. Enzinger
Dana-Farber Cancer Institute(US)
Publications by Year
Research Areas
Gastric Cancer Management and Outcomes, Esophageal Cancer Research and Treatment, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research
Most-Cited Works
- → Esophageal Cancer(2003)2,510 cited
- → Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer(2018)1,796 cited
- → Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology(2022)1,640 cited
- → Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study(2021)1,510 cited
- → Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology(2017)1,366 cited
- → Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer(2020)1,150 cited
- → Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer(2020)1,097 cited
- → Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology(2019)1,084 cited
- → Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial(2023)642 cited
- → Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors(2006)516 cited